Recombinant Human IFN-gamma Protein 285-IF-100 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemRecombinant Human IFN-gamma Protein
CompanyR&D Systems, a Bio-Techne Brand
Price $421.00Supplier Page View Company Product Page
Catalog Number285-IF-100
SpeciesHuman
Molecule NameIFN-gamma
Size100 ug (also 25 ug, 1 mg)
Source/Expression SystemE. coli-derived Recombinant Human IFN-gamma Protein
FormatLyophilized from a 0.2 µm filtered solution in Sodium Succinate, Mannitol and Tween® 80 with BSA as a carrier protein
Purity>97%, by SDS-PAGE under reducing conditions and visualized by silver stain
Molecular WeightObserved: 17 kDa, reducing conditions
Theoretical: 16.9 kDa
ApplicationsBioactivity
Conjugate/TagUnconjugated
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution
NCBI Full Gene Nameinterferon gamma
NCBI Gene AliasesIFG, IFI, IMD69

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Messenger RNA delivery to islet β cells using conjugated lipid nanoparticlesCell Reports MedicineMarch 17, 2026Jacob R. Enriquez, Zhengjie Zhou, Jennifer B. Nelson, Fei Huang, Kayla T. Figatner, Advaita Chakraborty, Sarida Pratuangtham, Brian Xi, Sarah C. May, Matthew V. Tirrell, et al.absence of a proinflammatory cytokine (PIC) cocktail containing 1000 IU/mL human IFN-γ (R&D Systems; 285-IF-100) and 50 IU/mL human IL-1β (R&D Systems; 201-LB-005). Cell lines and primary cultures MIN6 mouse β

(2) Putative α7-selective ligands interact with α9-containing nicotinic acetylcholine receptors and modulate immune functions of human mononuclear phagocytesFront ImmunolMarch 11, 2026Mona Mobasher, Arik J. Hone, Malin Pilzecker, Daria Bozic, Andreas Hecker, J. Michael McIntosh, Karl N. Kirschner, Veronika Grau, Roger L. Papke, Hina Andleeb, et al.Germany) and recombinant human interferon (INF)-γ from R&D Systems (Minneapolis, MN, United States; Cat# 285-IF-100). PMA, S24795 and PNU-282987 were dissolved in DMSO. Nigericin was dissolved in ethanol. When appropriate,

(3) MAPK Pathway Mutations Emerge in Mutant-IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the Interferon ResponseClinical Cancer ResearchMarch 2, 2026Jinkai Wan, Hatice Duygu Saatcioglu, Haley Ellis, Elia Aguado-Fraile, Qin Xu, Hiroshi Kondo, Robert T. Manguso, Ilaria Gritti, Bryanna L. Norden, Carolina Noble, et al.(MedChemExpress, cat. #HY-1876). IFNγ (10 ng/mL; Recombinant Human IFN-gamma Protein, R&D Systems, cat. #285-IF-100) was added during the final 2 days of treatment. For experiments involving RAS inhibitors (MRTX1133

(4) Homotypic SLAMF1:SLAMF1 interactions between innate T cells and neutrophils activate fungal killing by neutrophilsbioRxivFebruary 23, 2026Lindsay S. Lau, Sarah Lichtenberger, Cleison Ledesma Taira, Bruce S. Klein, Marcel Wüthrichto a volume of 150 μl with cRPMI. For positive control group, human recombinant IFN-g (R&D Systems 285-IF-100) in cRPMI was added to the top well for a final concentration of 150U/ml.[23] The bottom well was seeded

(5) Up-regulation of an epithelial miRNA is associated with immune evasion in progressive bronchial premalignant lesionsCancer Immunology ResearchFebruary 11, 2026Boting Ning, Darren J. Chiu, Roxana M. Pfefferkorn, Erin Cullinane, Yohana Kefella, Erin Kane, Valerie Reyes-Ortiz, Gang Liu, Xiaohui Zhang, Hanqiao Liu, et al.transfection, cells were stimulated with IFN-γ (Recombinant Human IFN-gamma Protein, R&D systems Cat#285-IF-100) at a concentration of 80ng/mL. Following 24 hours of stimulation, cells were harvested for qRT-PCR

(6) Pericentromeric Transcription of Novel Pathogen-Related Human GPS Genes in Cancers is Regulated by C19MC miRNAs, CEBPB, IFN-γ, and IFN-βResearchSquareFebruary 4, 2026Goodwin Jinesh, Isha Godwin, Marco Napoli, Elsa Flores, Andrew BrohlmiRNeasy Mini Kit (50) (Qiagen, Cat.# 217004). Cytokines and treatment conditions: IFN-γ (R&D Systems, Cat.# 285-IF-100, 1nM / 17 ng/ml for 24 h.), IFN-β (R&D Systems, Cat.# 8499-IF-010, 1nM / 20 ng/ml for 24 h.). Chemical

(7) Intradermal delivery of lipophilic siRNAs enables prolonged skin retention and sustained gene silencing in a porcine modelNature CommunicationsFebruary 3, 2026Hassan H. Fakih, Mohammad Zain UI Abideen, Mohamad Omar Rachid, Katherine Y. Gross, Thomas J. R. Ormsby, Vella M. Ross, Rosemary Gagnon, Christopher Dahlke, Raymond C. Furgal, Clemens Lochmann, et al.biopsies were treated with new media containing 10 ng/mL recombinant human IFN-γ protein (R&D System, #285-IF-100) and 10 ng/mL recombinant human TNF protein (R&D System, #210-TA-020). mRNA expression was measured

(8) Bi‐Functional Topospecific Nanoparticles to Promote Immune‐Tumor Cell Engagement as A New Immunotherapeutic StrategyAdvanced MaterialsJanuary 1, 2026Alba Ortuño‐Bernal, Sandra Clara‐Trujillo, Elena Lucena‐Sánchez, Francisco J. Hicke, Andrea Escudero, Sandra Pradana‐López, Nelia Jiménez‐Alduan, Paula Díez, Alba García‐Fernández, Ramón Martínez‐Máñezseeded and stimulated overnight with 200 ng mL−1 human recombinant interferon‐γ (IFN‐γ) (Bio‐Techne, 285‐IF‐100). SK‐MEL‐103 seeding densities were: 5000 cells/well in a 96‐well white plate for bioluminescence assays

(9) Positionally distinct interferon-stimulated dermal immune-acting fibroblasts promote neutrophil recruitment in Sweet's syndromeJournal of Allergy and Clinical ImmunologyOctober 1, 2025Kellen J. Cavagnero, Julie Albright, Fengwu Li, Edward Liu, Tatsuya Dokoshi, Rachael Bogle, Joseph Kirma, J. Michelle Kahlenberg, Allison C. Billi, Jennifer Fox, et al.rhTNF-α (R&D Systems; catalog no. 210-TA-005; dose 10 ng/mL), or rhIFN-γ (R&D Systems; catalog no. 285-IF-100; dose 5 ng/mL). After 6 hours of stimulation, cells were lysed with RNA lysis buffer (Qiagen [Hilden,

(10) IFNγ regulates MR1 transcription and antigen presentationFrontiers in ImmunologySeptember 26, 2025Megan E. Huber, Emily A. Larson, Taylor N. Lust, Chelsea M. Heisler, Melanie J. Harriffalbumin as per manufacturer recommendations. Final concentrations used were: 66 ng/ml IFNγ (R&D Systems 285-IF-100), 66 ng/ml IFNβ (R&D Systems 8199-IF-010), 132 ng/ml IFNλ (PeproTech 300-02K), 66 ng/ml TNFα (R&D Systems

(11) Phytochemical Profiling and Anti-Inflammatory Activity of Rubus parvifolius Leaf Extract in an Atopic Dermatitis ModelLife (Basel)September 1, 2025Junseong Kim, Derrick Kakooza, Chang-Dae Lee, Su-Young Jung, Kyung Choi, Sung-Kwon Moon, Hoon Kim, Sanghyun Leehuman tumor necrosis factor-alpha (TNF-α; Cat. No. 210-TA-100) and interferon-gamma (IFN-γ; Cat. No. 285-IF-100) were obtained from R&D Systems (Minneapolis, MN, USA). Fetal bovine serum (FBS; Cat. No. 35-015-CV)

(12) Endolysosomal damage surveillance enables rapid inflammasome sensing of pathogensCell reportsAugust 26, 2025Shivcharan S, Younis DA, Wright SS, Wang C, Behl B, Shumba P, Delgado KN, Chawla AK, Alto NM, Panjwani N, et al.

(13) Phosphatidic acid production on the vacuole harboring Legionella pneumophila is a signal for recognition of interferon-induced GTPasesProceedings of the National Academy of Sciences of the United States of AmericaAugust 12, 2025Oide H, Kubori T, Nagai H, Nozawa T, Nakagawa I, Sasai M, Yamamoto M, Arasaki K.

(14) Identifying a potential role of immune cells in gadolinium deposition within the brainFluids Barriers CNSJuly 29, 2025Dixy Parakkattel, Nico Ruprecht, Peter Broekmann, Sarah Guimbal, Chiara Stüdle, Sasha Soldati, Johannes T. Heverhagen, Britta Engelhardt, Hendrik von Tengg-Kobligkrecombinant human TNFα (R&D systems, Cat#210-TA-020) and recombinant human IFNγ (R&D systems, Cat #285-IF-100) diluted in conditioned media (CM) collected from SMLC from same donor, for 16–24 h at 37 °C, 5% CO2.

(15) Immunogenicity of autologous and allogeneic human primary cholangiocyte organoid cellular therapiesCell Rep MedJuly 15, 2025Sandra Petrus-Reurer, Winnie Lei, Olivia Tysoe, Maelle Mairesse, Adrian Baez-Ortega, Julia Jones, Thomas Tan, Sylvia Rehakova, Krishnaa T. Mahbubani, Cara Brodie, et al.II FL (Life Technologies). 2 days Interferon-gamma (IFN-ɣ) pre-stimulated (100 ng/mL, R&D Systems, 285-IF-100) PCOs (passage 10) were single celled as described above and plated at a cell density range of 9x105

(16) Comparative virulence analysis of seven diverse strains of Orientia tsutsugamushi reveals a multifaceted and complex interplay of virulence factors responsible for diseasePLOS PathogensJune 30, 2025Panjaporn Chaichana, Naphat Satapoomin, Chitrasak Kullapanich, Suthida Chuenklin, Aisha Mohammad, Manutsanun Inthawong, Erin E. Ball, Thomas P. Burke, Piyanate Sunyakumthorn, Jeanne Salje400 U/ml of recombinant mouse (R&D Systems, cat# 485-MI-100, USA) or human IFN-γ (R&D Systems, cat# 285-IF-100, USA) for BMDM and human primary macrophages, respectively. Bacteria were then added in triplicate after

(17) The immune checkpoint TIM-3/HMGB-1 axis in myocardial infarctionnpj Cardiovascular HealthJune 27, 2025Laura I. Yousif, Aukje G. Sijtema, Ymke Appels, Elles M. Screever, Irene V. van Blokland, Roy Oelen, Hilde E. Groot, Tamás G. Gergely, Márton Kocsis, Przemyslaw Leszek, et al.group). For M1, cells were stimulated with 10 pg/mL LPS (L5293, Sigma-Aldrich) and 20 ng/mL IFN-γ (285-IF-100, R&D Systems). For M2, cells were stimulated with 20 ng/mL human recombinant IL-4 (130-093-917, Miltenyl

(18) Acute inflammation triggered by two lightweight hernia meshes: a comparative in vitro and retrospective cohort studyHerniaJune 17, 2025Martin Reichert, Bernadet Massambo, Anca-Laura Amati, Veronika Grau, Katrin Richter, Andreas Heckerwith 10 ng/ml recombinant human interferon (IFN)-γ (R&D Systems, Minneapolis, MN, United States; Cat# 285-IF-100) and 10 ng/ml lipopolysaccharide (LPS, E. coli O111:B4, Merck, Cat# L2630) for 72 h. On day 5 of differentiation,

(19) Inhibition of placental trophoblast fusion by guanylate-binding protein 5Science advancesMay 9, 2025Krchlikova V, Braun E, Weiss J, Stafl K, Jech L, Badarinarayan SS, Lotke R, Travnicek M, Baur C, Stark P, et al.increasing amounts of valproate (Sigma-Aldrich, catalog no. 676380) or IFN-γ (R&D Systems, catalog no. 285-IF 100). Cell fusion was triggered by addition of 10 μM forskolin (Sigma-Aldrich, catalog no. F6886). To monitor

(20) Antitumor CD4+ T Helper 1 Cells Target and Control the Outgrowth of Disseminated Cancer CellsCancer Immunology ResearchMay 2, 2025Ganesan Ramamoorthi, Marie Catherine Lee, Carly M. Farrell, Colin Snyder, Saurabh K. Garg, Amy L. Aldrich, Vincent Lok, William Dominguez-Viqueira, Sy K. Olson-Mcpeek, Marilin Rosa, et al.233-FB-025, R&D Systems) with a 5% CO2 supply. DCCs were treated with or without IFN-γ (20 ng/mL; Cat. No. 285-IF-100, R&D Systems) for 24 to 72 hours. For the tumorigenicity assay, patient’s viable BM DCCs (30,000 cells;

Be the First to Write a Review!

Recombinant Human IFN-gamma Protein

IFN-gamma Protein

IFN-gamma Protein

IFN-gamma Protein

IFN-gamma Protein

Recombinant Human IFN-gamma Protein from R&D Systems, a Bio-Techne Brand

Description

R&D Systems, a Bio-Techne Brand

Citations (565)

Reviews

Recombinant Human IFN-gamma Protein from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map